Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Saravut Weroha

Medical Oncology Rochester, MN Medical Doctor

NPI 1043415144 CMS profile 392903

200 1St St Sw, Rochester, MN 55905

Open in the dashboard

General payments

$18,088

21 records reported · program years 2019–2025

Research payments

$1,270

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$129,781 paid to institutions, not to them · program years 2020–2022

Through program year 2025, Saravut Weroha of Rochester, MN is reported in the CMS Open Payments database as having received $18,088 across 21 general payments and $1,270 in research payments paid to them. Separately, studies naming them as principal investigator received $129,781 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 72nd percentile of Medical Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,409 3
2024 General $109 1
2023 General $2,502 3
2023 Research $1,270 2
2021 General $2,055 1
2019 General $10,013 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Saravut Weroha
  • Medical Oncology median
  • Middle half of Medical Oncology
  • National median

In program year 2025, general payments to Saravut Weroha were reported at $3,409. Among 3,316 Medical Oncology profiles paid that year, the median was $1,128 and the middle half received between $147 and $5,675.

Show as a table
Year Saravut Weroha Medical Oncology median Middle half National median
2019 $10,013 $968 $140–$6,658 $163
2020 $0 $747 $102–$5,891 $114
2021 $2,055 $430 $50–$4,098 $132
2022 $0 $812 $127–$4,907 $149
2023 $2,502 $957 $144–$5,248 $160
2024 $109 $1,042 $149–$5,650 $164
2025 $3,409 $1,128 $147–$5,675 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Merck Sharp & Dohme Corporation $9,911 12 payments
  2. AstraZeneca Pharmaceuticals LP $4,507 3 payments
  3. AbbVie, Inc. $2,465 2 payments
  4. Eli Lilly and Company $1,053 2 payments
  5. Genentech USA, Inc. $102 1 payment
  6. ImmunoGen, Inc. $50 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $15,809 5 payments
  2. Travel and Lodging $1,616 4 payments
  3. Food and Beverage $664 12 payments
Products named General payments · program years 2019–2025
  1. LYNPARZA $4,507 3 payments
  2. ELAHERE Oncology $2,465 2 payments
  3. Avastin $102 1 payment
  4. Elahere Oncology $50 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Pfizer Inc. $1,270 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

109

Median for Medical Oncology: 414

Drug cost

$1,128

Median for Medical Oncology: $849,427

Branded share of claims

0%

Median for Medical Oncology: 28.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Prochlorperazine Maleate Generic 27 $326
Ondansetron Hcl Generic 23 $310
Olanzapine Generic 19 $270
Dexamethasone Generic 40 $222

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,431 Part D prescribers listed as Medical Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 107 billing codes

Paid by Medicare

$706,509

Of which drugs: $675,949

Medicare patients

196

Average age 72

Services billed

27,120

125 women, 71 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 64%
Cancer 49%
Arthritis 31%
Chronic kidney disease 24%
Ischemic heart disease 20%
Depression 20%
Diabetes 19%
Heart failure 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, pembrolizumab, 1 mg J9271 Office 17 3,600 $152,188
Injection, daratumumab, 10 mg and hyaluronidase-fihj J9144 Office 14 3,240 $127,152
Leuprolide acetate (for depot suspension), 7.5 mg J9217 Office 12 55 $7,839
Injection, carboplatin, 50 mg J9045 Office 15 118 $343
Injection, fosaprepitant, 1 mg J1453 Office 17 2,700 $323
Injection, palonosetron hcl, 25 mcg J2469 Office 28 290 $229
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 22 230 $21
Injection, ondansetron hydrochloride, per 1 mg J2405 Office 26 244 $18
Injection, diphenhydramine hcl, up to 50 mg J1200 Office 13 13 $9

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ELAHERE
  • AbbVie, Inc. $109
$109 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

23 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record